Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 12/20 | 0.40 |
| ▸ | HTR1A | P08908 | 9/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL706482 | 0.90 | HTR1A (0.40) | MAPTHTR1AOPRM1ALDH1A1MEN1 | |
| SCHEMBL704636 | 0.84 | HSD11B1 (0.46) | MAPTADRA1BHTR1AADRA1AADRA1D | |
| SCHEMBL704389 | 0.80 | DRD2 (0.48) | HSD11B1ALDH1A1MEN1KMT2A | |
| SCHEMBL704843 | 0.70 | ERCC1 (0.42) | HSD11B1ALDH1A1MEN1KMT2A | |
| SCHEMBL704493 | 0.70 | AR (0.42) | MAPTHTR1AHSD11B1MEN1KMT2A | |
| SCHEMBL705521 | 0.68 | HSD11B1 (0.46) | OPRM1HSD11B1MEN1KMT2A | |
| SCHEMBL705534 | 0.68 | MAPT (0.50) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL703315 | 0.68 | MET (0.36) | ADRA1DOPRM1MEN1MAPK1KMT2A | |
| SCHEMBL1116570 | 0.67 | MAOB (0.43) | MAPT | |
| SCHEMBL293416 | 0.66 | MAPT (0.48) | MAPTADRA1BHTR1AOPRM1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280970-B1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | claimed |
| US-8124636-B2 | Imidazolidinone derivatives as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | claimed |
| EP-2280970-A1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-02-09 | — | — | EP | claimed |
| WO-2009132986-A1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | claimed |
| US-20090275573-A1 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors | HOFFMANN-LA ROCHE, INC. | 2009-11-05 | — | — | US | claimed |
| EP-2280970-B1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8124636-B2 | Imidazolidinone derivatives as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2280970-A1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009132986-A1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090275573-A1 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors | HOFFMANN-LA ROCHE, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275573-A1 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors | HSD11B1, HSD17B1, HSD17B11 | MAPT 3361/4885ADRA1B 194/4885HTR1A 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.